Paper Details

  1. Home
  2. Paper Details

[Collecting duct carcinoma].

Author: EnzmannThomas, GüntherMarlis, SondermannMarcus

English AbstractA summary of a research paper/publication written in English for a wider audience.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Collecting duct carcinoma is a rare and aggressive type of kidney cancer. This article discusses the current treatment options for this disease, including surgery, chemotherapy, immunotherapy, and targeted therapy.
Paper Details　
Original Abstract of the Article :
Collecting duct carcinoma (Bellini duct carcinoma) is a very rare disease with poor prognosis. Primary tumor surgery is not advisable, even though it is the therapy of choice for suspected malignant space-occupying renal masses. Chemotherapy seems to be inferior to new therapeutic concepts based on ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1007/s00120-022-01830-7

データ提供：米国国立医学図書館（NLM）

Collecting Duct Carcinoma: A Rare and Aggressive Renal Cancer

Collecting duct carcinoma (CDC), a rare and aggressive type of renal cancer, presents significant challenges in diagnosis and treatment. This review summarizes the current understanding of CDC, focusing on its poor prognosis and the complexities of therapeutic approaches.

Seeking Effective Therapies for a Rare and Aggressive Cancer

Due to the rarity of CDC, clinical trials have been limited, making it difficult to establish definitive treatment guidelines. While surgery is the preferred approach for suspected renal malignancies, it is generally not recommended for CDC due to its aggressive nature. Chemotherapy has shown limited efficacy, and the review highlights the potential of newer therapies such as immunotherapy with nivolumab and axitinib, and targeted therapy with cabozantinib. However, the authors acknowledge the need for further investigation and caution about the side effects of these therapies.

A Focus on Individualized Care for CDC Patients

This review emphasizes the importance of a personalized approach to managing CDC patients. Given the rarity and aggressiveness of the disease, open communication between doctors and patients is essential to discuss treatment options and weigh potential benefits against potential risks. The focus should be on maximizing quality of life while exploring all available therapeutic avenues.

Dr. Camel's Conclusion

Just as a camel adapts to the harsh conditions of the desert, healthcare professionals must adapt their approach to the challenges of treating collecting duct carcinoma. This review underscores the need for personalized care, continued research, and a multidisciplinary approach to managing this rare and aggressive cancer.
Date :
  1. Date Completed 2022-12-15
  2. Date Revised 2022-12-15
Further Info :

Pubmed ID

35428926

DOI: Digital Object Identifier

10.1007/s00120-022-01830-7

Related Literature

Article Analysis
・Side Effects of cabozantinib
SNS
PICO Info
in preparation
Languages

German

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.